Groupe Hospitalier Bichat - Claude Bernard 46, rue Henri-Huchard
Paris, Île-de-France Region, 75018, France
NCT Number: NCT01648933
The study aims at assessing diagnostic and therapeutic impact of Rubidium-82 PET in cardiac sarcoidosis.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Paris, Île-de-France Region, 75018, France
The presence of cardiac involvement is a serious complication of sarcoidosis. Early diagnosis is challenging since it relies on an array of clinical, biological and imaging abnormalities. Myocardial perfusion imaging with sestamibi is currently a major feature of the diagnosis, since it allows to evidence both microcirculatory impairments and scar. However, some technical limitations are inherent to SPECT, mainly poor spatial resolution and lack of attenuation correction, resulting in the absence of flow quantification. Rubidium-82 (Rb) PET proved to be more sensitive and specific than sestamibi SPECT in the diagnosis of coronary artery disease. Furthermore, it allows noninvasive measurement of coronary flow reserve. Finally, it exposes patients to lower radiation dose than SPECT. Therefore, Rb PET may help to better identify cardiac involvement of sarcoidosis, and hence to better select those patients who require high-dose steroids.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Myocardial Perfusion Imaging
Time frame: 60 days
to assess diagnostic and therapeutic impacts of myocardial perfusion analysis with Rubidium-82 PET in cardiac sarcoidosis.
Time frame: 9 months
to compare the cost between the two exams and the health-economic impact of Sestamibi SPECT and Rb-PET as MPI agents in cardiac sarcoidosis.
Assistance Publique - Hôpitaux de Paris
Other
Acronym: PARCS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03814317
Cardiovascular Diseases, Hemic and Lymphatic Diseases
Gainesville, Florida, United States
View Trial DetailsNCT01610843
Hemic and Lymphatic Diseases, Hypersensitivity
Iowa City, Iowa, United States
View Trial DetailsNCT01687517
Hemic and Lymphatic Diseases, Hypersensitivity
Paris, France
View Trial DetailsNCT06907953
COVID-19, Chronic Disease
New York, United States
View Trial Details